214 related articles for article (PubMed ID: 36411392)
1. Insights into distinct signaling profiles of the µOR activated by diverse agonists.
Qu Q; Huang W; Aydin D; Paggi JM; Seven AB; Wang H; Chakraborty S; Che T; DiBerto JF; Robertson MJ; Inoue A; Suomivuori CM; Roth BL; Majumdar S; Dror RO; Kobilka BK; Skiniotis G
Nat Chem Biol; 2023 Apr; 19(4):423-430. PubMed ID: 36411392
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Evolution of G Protein-Biased μ-Opioid Receptor Agonists.
Wang H; Hetzer F; Huang W; Qu Q; Meyerowitz J; Kaindl J; Hübner H; Skiniotis G; Kobilka BK; Gmeiner P
Angew Chem Int Ed Engl; 2022 Jun; 61(26):e202200269. PubMed ID: 35385593
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.
Mafi A; Kim SK; Goddard WA
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16346-16355. PubMed ID: 32601232
[TBL] [Abstract][Full Text] [Related]
4. Molecular insights into the biased signaling mechanism of the μ-opioid receptor.
Cong X; Maurel D; Déméné H; Vasiliauskaité-Brooks I; Hagelberger J; Peysson F; Saint-Paul J; Golebiowski J; Granier S; Sounier R
Mol Cell; 2021 Oct; 81(20):4165-4175.e6. PubMed ID: 34433090
[TBL] [Abstract][Full Text] [Related]
5. Molecular recognition of morphine and fentanyl by the human μ-opioid receptor.
Zhuang Y; Wang Y; He B; He X; Zhou XE; Guo S; Rao Q; Yang J; Liu J; Zhou Q; Wang X; Liu M; Liu W; Jiang X; Yang D; Jiang H; Shen J; Melcher K; Chen H; Jiang Y; Cheng X; Wang MW; Xie X; Xu HE
Cell; 2022 Nov; 185(23):4361-4375.e19. PubMed ID: 36368306
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of fentanyl mediated β-arrestin biased signaling.
de Waal PW; Shi J; You E; Wang X; Melcher K; Jiang Y; Xu HE; Dickson BM
PLoS Comput Biol; 2020 Apr; 16(4):e1007394. PubMed ID: 32275713
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of Novel Biased μ-Opioid-Receptor (μOR) Agonists.
Ma M; Sun J; Li M; Yu Z; Cheng J; Zhong B; Shi W
Molecules; 2019 Jan; 24(2):. PubMed ID: 30641969
[TBL] [Abstract][Full Text] [Related]
8. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.
Lu JJ; Polgar WE; Mann A; Dasgupta P; Schulz S; Zaveri NT
Mol Pharmacol; 2021 Jul; 100(1):7-18. PubMed ID: 33958480
[TBL] [Abstract][Full Text] [Related]
9. Delineating the Ligand-Receptor Interactions That Lead to Biased Signaling at the μ-Opioid Receptor.
Kelly B; Hollingsworth SA; Blakemore DC; Owen RM; Storer RI; Swain NA; Aydin D; Torella R; Warmus JS; Dror RO
J Chem Inf Model; 2021 Jul; 61(7):3696-3707. PubMed ID: 34251810
[TBL] [Abstract][Full Text] [Related]
10. An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.
Groer CE; Tidgewell K; Moyer RA; Harding WW; Rothman RB; Prisinzano TE; Bohn LM
Mol Pharmacol; 2007 Feb; 71(2):549-57. PubMed ID: 17090705
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Structural Explorations of G-Protein Biased μ-Opioid Receptor Agonists.
Li X; Guo Y; Li J; Yu Z; Cheng J; Ren F; Jia H; Zhang Y; Cui S; Zhang T; Shi W
ChemMedChem; 2022 Dec; 17(24):e202200416. PubMed ID: 36210341
[TBL] [Abstract][Full Text] [Related]
12. Noribogaine is a G-protein biased κ-opioid receptor agonist.
Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
[TBL] [Abstract][Full Text] [Related]
13. Carfentanil is a β-arrestin-biased agonist at the μ opioid receptor.
Ramos-Gonzalez N; Groom S; Sutcliffe KJ; Bancroft S; Bailey CP; Sessions RB; Henderson G; Kelly E
Br J Pharmacol; 2023 Sep; 180(18):2341-2360. PubMed ID: 37005796
[TBL] [Abstract][Full Text] [Related]
14. Probing Allosteric Regulation Mechanism of W7.35 on Agonist-Induced Activity for μOR by Mutation Simulation.
Zhang F; Chen X; Chen J; Xu Y; Li S; Guo Y; Pu X
J Chem Inf Model; 2022 Nov; 62(21):5120-5135. PubMed ID: 34779608
[TBL] [Abstract][Full Text] [Related]
15. Biased Agonism: Lessons from Studies of Opioid Receptor Agonists.
Kelly E; Conibear A; Henderson G
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():491-515. PubMed ID: 36170657
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of bitopic ligands for the µ-opioid receptor.
Faouzi A; Wang H; Zaidi SA; DiBerto JF; Che T; Qu Q; Robertson MJ; Madasu MK; El Daibani A; Varga BR; Zhang T; Ruiz C; Liu S; Xu J; Appourchaux K; Slocum ST; Eans SO; Cameron MD; Al-Hasani R; Pan YX; Roth BL; McLaughlin JP; Skiniotis G; Katritch V; Kobilka BK; Majumdar S
Nature; 2023 Jan; 613(7945):767-774. PubMed ID: 36450356
[TBL] [Abstract][Full Text] [Related]
17. Molecular insights into the allosteric coupling mechanism between an agonist and two different transducers for μ-opioid receptors.
Zhang F; Yuan Y; Chen Y; Chen J; Guo Y; Pu X
Phys Chem Chem Phys; 2022 Mar; 24(9):5282-5293. PubMed ID: 35170592
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Intracellular Signaling Activities of κ-Opioid Receptor Agonists, Nalfurafine Analogs; Focusing on the Selectivity of G-Protein- and β-Arrestin-Mediated Pathways.
Yamaguchi M; Miyano K; Hirayama S; Karasawa Y; Ohshima K; Uezono E; Komatsu A; Nonaka M; Fujii H; Yamaguchi K; Iseki M; Hayashida M; Uezono Y
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296658
[TBL] [Abstract][Full Text] [Related]
19. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.
French AR; van Rijn RM
Pharmacol Res; 2022 Mar; 177():106091. PubMed ID: 35101565
[TBL] [Abstract][Full Text] [Related]
20. Identification of the First Marine-Derived Opioid Receptor "Balanced" Agonist with a Signaling Profile That Resembles the Endorphins.
Johnson TA; Milan-Lobo L; Che T; Ferwerda M; Lambu E; McIntosh NL; Li F; He L; Lorig-Roach N; Crews P; Whistler JL
ACS Chem Neurosci; 2017 Mar; 8(3):473-485. PubMed ID: 27744679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
